Brown Advisory Inc. decreased its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 1.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 2,293,203 shares of the company's stock after selling 45,166 shares during the period. Brown Advisory Inc. owned 7.95% of Establishment Labs worth $93,574,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the business. Guided Capital Wealth Management LLC purchased a new position in Establishment Labs during the 1st quarter valued at about $1,794,000. Elevation Point Wealth Partners LLC acquired a new stake in Establishment Labs in the 1st quarter worth approximately $207,000. Patriot Financial Group Insurance Agency LLC acquired a new stake in Establishment Labs in the 1st quarter worth approximately $234,000. Toronto Dominion Bank acquired a new stake in Establishment Labs in the 4th quarter worth approximately $24,879,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Establishment Labs by 15.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock worth $2,196,000 after purchasing an additional 6,307 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts recently commented on ESTA shares. Wall Street Zen upgraded shares of Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th. Citigroup boosted their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a report on Wednesday. BTIG Research began coverage on shares of Establishment Labs in a research note on Friday, May 16th. They set a "buy" rating and a $62.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $48.00 target price on shares of Establishment Labs in a research report on Friday, June 13th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $51.80.
View Our Latest Stock Analysis on ESTA
Establishment Labs Stock Performance
Shares of NASDAQ ESTA traded up $1.71 during mid-day trading on Thursday, hitting $46.77. 96,425 shares of the company were exchanged, compared to its average volume of 476,826. The company has a quick ratio of 2.05, a current ratio of 3.36 and a debt-to-equity ratio of 5.72. The stock has a 50 day simple moving average of $37.68 and a 200-day simple moving average of $36.94. Establishment Labs Holdings Inc. has a 1-year low of $26.56 and a 1-year high of $52.41. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -15.07 and a beta of 0.80.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The company had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. During the same quarter last year, the company earned ($0.58) earnings per share. Establishment Labs's quarterly revenue was up 11.3% compared to the same quarter last year. On average, sell-side analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.
Establishment Labs Company Profile
(
Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Further Reading
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
